• Price (EUR)51.74
  • Today's Change-0.62 / -1.18%
  • Shares traded0.00
  • 1 Year change+18.13%
  • Beta--
Data delayed at least 15 minutes, as of Mar 21 2023 07:06 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.

  • Revenue in JPY (TTM)737.10bn
  • Net income in JPY26.71bn
  • Incorporated1941
  • Employees11.32k
  • Location
    Eisai Co LtdEisai Main Bldg., 4-6-10, KoishikawaBUNKYO-KU 112-8088JapanJPN
  • Phone+81 338173700
  • Fax+81 338113305
  • Websitehttps://www.eisai.co.jp/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4523:TYO since
Sunplanet Co LtdDeal completed30 May 202230 May 2022Deal completed35.89%2.98m
Arteryex IncDeal completed31 Mar 202231 Mar 2022Deal completed24.45%--
Data delayed at least 20 minutes, as of Mar 20 2023 06:00 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.